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Abstract 10 
CX3CL1 (fractalkine), the sole member of chemokine CX3C family, is implicated in 11 
inflammatory and neuropathic pain via activating its receptor CX3CR1 on neural cells 12 
in spinal cord. However, it has not been fully elucidated whether CX3CL1 or CX3CR1 13 
contributes to the development of morphine tolerance. In this study, we found that 14 
chronic morphine exposure did not alter the expressions of CX3CL1 and CX3CR1 in 15 
spinal cord. And neither exogenous CX3CL1 nor CX3CR1 inhibitor could affect the 16 
development of morphine tolerance. The cellular localizations of spinal CX3CL1 and 17 
CX3CR1 changed from neuron and microglia, respectively, to all the neural cells during 18 
the development of morphine tolerance. A microarray profiling revealed that 15 19 
members of chemokine family excluding CX3CL1 and CX3CR1 were up-regulated in 20 
morphine-treated rats. Our study provides evidence that spinal CX3CL1 and CX3CR1 21 
may not be involved in the development of morphine tolerance directly. 22 
3 
 
Introduction 1 
Morphine is the most important and frequently used opioid for acute and chronic pain 2 
in clinical practice. However, repeated usage of morphine can induce drug tolerance, a 3 
consequence requiring higher doses of morphine to maintain the same analgesic effect. 4 
Dose escalation of morphine could potentially cause serious side effects including 5 
respiratory depression [1], hypotension, nausea, constipation, dizziness and addiction 6 
[2]. Morphine tolerance could hinder the clinical utilization of morphine and impair the 7 
quality of life in patients. Thereby, understanding the mechanism of morphine tolerance 8 
is critical for improving pain management. 9 
Chemokines play the pivotal roles in neuroinflammation, nerve injury-induced pain [3-10 
5] and morphine analgesia [6-8]. CX3CL1 (fractalkine) is the only member of 11 
chemokine CX3C family [9] and activates its sole receptor CX3CR1. Previous studies 12 
have demonstrated that intrathecal injection of CX3CR1 neutralizing antibody can 13 
effectively delay the development of mechanical allodynia and thermal hyperalgesia in 14 
neuropathic pain, inflammatory pain and cancer pain [3,10,11]. In addition, CX3CL1 15 
has been reported to be involved in diminishing the analgesic effect of opioids in 16 
periaqueductal grey [12]. Thus, CX3CL1 plays an important role in the mechanisms of 17 
chronic pain. 18 
In central nervous system, microglia are generally regarded as the source and target of 19 
chemokines [13]. Microglia can regulate and receive chemokine signal between 20 
astrocyte and neuron through autocrine and paracrine communications, thus 21 
contributing to the development of neuropathic pain [14] and traumatic brain injury 22 
[15]. Although it is clear that microglia activation is involved in morphine tolerance 23 
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[16,17], the potential signals that causing glial activation have not been well understood. 1 
Morphine tolerance and chronic pain may share the similar cellular mechanisms. 2 
Previous study reported that CX3CL1 is mainly released by neurons and its receptor 3 
CX3CR1 is primarily expressed on microglia [18]. As CX3CL1 plays an important role 4 
in chronic pain, these results indicate a potential involvement of CX3CL1/CX3CR1 5 
signaling axis in the activation of microglia, and thus the mechanism of morphine 6 
tolerance. Thereby, the present study was designed to investigate the possible roles of 7 
spinal CX3CL1/CX3CR1 in the development of morphine tolerance in rats. 8 
Materials and methods 9 
Animals 10 
Specific pathogen free adult male Sprague-Dawley rats, weighing 220-240 g, were 11 
purchased from Laboratory Animal Center, Tongji Medical College, Huazhong 12 
University of Science & Technology. Animals were housed under controlled conditions 13 
(22±0.5 °C, relative humidity 40-60 %, alternate light-dark cycles, food and water ad 14 
libitum). To keep the integrity of catheter, rats were housed individually after surgery. 15 
All experimental procedures and protocols were reviewed and approved by 16 
Experimental Animal Care and Use Committee of Tongji Medical College, Huazhong 17 
University of Science &Technology, and carried out in accordance with the National 18 
Institutes of Health Guidelines for the Care and Use of Laboratory Animals. 19 
Intrathecal catheterization 20 
Lumbosacral indwelling catheters were constructed and planted using a lumbar 21 
approach, as described previously [19]. Briefly, rats were deeply anesthetized with 1 % 22 
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pentobarbital sodium [60 mg/kg, intraperitoneal injection (i.p.)]. The lumbar region of 1 
rat was shaved, and intrathecal catheterization was performed by implanting a sterile 2 
PE-0503 catheter (outer diameter 0.5 mm, inner diameter 0.3 mm. Anilab Software & 3 
Instruments, Ningbo, China) into subarachnoid cavity between L4 and L5 vertebrae. 4 
The catheter was subcutaneously tunneled, externalized and fixed to the back of neck. 5 
Wounds were sutured after disinfection with 75 % (v/v) ethanol. Proper location of 6 
catheter was confirmed by a temporary motor block of both hind limbs after intrathecal 7 
injection of 10 μL of 2 % lidocaine. The rats were allowed a 7-day recovery period 8 
before the following experiments. Rats with hind limb paralysis or paresis after surgery 9 
were excluded and euthanized with overdose of pentobarbital sodium. 10 
Drugs administration 11 
The drugs used in this study were prepared as follows. Morphine hydrochloride was 12 
diluted by saline (North-East Pharmaceutical Group, China). Recombinant rat CX3CL1 13 
protein (rrCX3CL1, R&D, Minneapolis, MN, USA) was dissolved in saline and 14 
injected intrathecally (100 ng or 500 ng). Rabbit anti-rat CX3CR1 (Torrey Pine Biolabs, 15 
East Orange, NJ, USA) and placebo rabbit IgG (Sigma, St. Louis, MO, USA) were 16 
diluted by saline and administered intrathecally (5 μg or 10 μg). All drugs or vehicle 17 
solutions were injected 30 min before morphine administration in a volume of 5 μL 18 
followed by 10 μL of saline to flush the catheter. All the doses of each drug used in this 19 
study were determined according to the previous experiments [3,12,20]. 20 
Morphine tolerance 21 
To induce chronic tolerance to morphine, rats were intrathecally injected with morphine 22 
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(10 μg) twice daily for 7 days. Rats in the control group received an equivalent volume 1 
of saline at the same time points. The development of morphine tolerance was assessed 2 
by behavioral tests on day 1, 3, 5 and 7 [21]. 3 
Behavioral assessment 4 
Thermal pain thresholds in rats were measured by a tail-flick latency test [22] before 5 
drug administration and at 30 min after morphine administration on day 1, 3, 5, and 7 6 
[21]. Briefly, rats were placed in plastic containers to hold the body without restraining 7 
the head and tail, and one-third to the tip of tail was immersed into water. The 8 
temperature of water was adjusted to 50 ± 0.2 °C because this was the proper 9 
temperature to record an average tail-flick latency of 2 - 4 s in naïve rats. A cutoff time 10 
of 15 seconds was determined to prevent tail damage. The test was repeated three times 11 
and the mean of three trials was considered as the final latency. The percentage of 12 
maximal possible antinociceptive effect (%MPE) was calculated by comparing the test 13 
latency before (baseline, BL) and after drug injection (TL) using following 14 
equation: %MPE= [(TL-BL)/ (cutoff time-BL)] ×100. All behavioral tests were carried 15 
out under blind conditions. 16 
Quantitative real-time polymerase chain reaction (qRT-PCR) 17 
Under deep anesthesia with 1 % pentobarbital sodium, L1-L5 spinal cord segments of 18 
rats were quickly removed on day 7. Total RNA was extracted from tissue sample and 19 
the reverse transcription procedure was performed by using RNAiso Plus (Takara, 20 
Shiga, Japan) according to the manufacturer’s instructions. One microgram of total 21 
RNA from each sample was added into 20 μL reactive solution of reverse transcription, 22 
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respectively. Specific primers for rat CX3CL1, CX3CR1, mu opioid receptor (MOR) 1 
and endogenous control rat GAPDH were obtained from GeneCopoeia Company 2 
(USA). The catalogs of each primer were as following: CX3CL1 (RQP052632), 3 
CX3CR1 (RQP052471), MOR (RQP048316), GAPDH (RQP049537). StepOne Real-4 
Time PCR System (Applied Biosystems, USA) was used to conduct the qRT-PCR. 5 
Relative quantification of mRNA was performed by 2-∆∆Ct method. 6 
Western blots 7 
L1-L5 spinal cord segments of all animals were quickly removed and dissected. Total 8 
protein of spinal cord tissue from each group was extracted by using radio 9 
immunoprecipitation assay lysis buffer according to the manufacturer’s instructions 10 
(Beyotime, Wuhan, China). The protein concentration of supernatants was measured 11 
by using bicinchoninic acid assay. 50 μg protein from each sample was loaded on 10 % 12 
SDS-PAGE gel after boiling in the sample buffer. Electrophoresis was conducted at 60 13 
V constant voltage for stacking gel and 100 V for separating gel. The proteins were 14 
subsequently electro-transferred (200 mA, 60-90 min) to a PVDF membrane (Millipore, 15 
Bellerica, MA, USA). The membrane was blocked with 5 % BSA (Bovine Serum 16 
Albumin) for 1 h at room temperature followed by incubating with the following 17 
primary antibodies: mouse anti-ionized calcium-binding adapter molecule 1 (Iba1) 18 
antibody (1: 200, Santa Cruz, Dallas, TX, USA), goat anti-CX3CL1 antibody (1: 50, 19 
R&D, Minneapolis, MN, USA), rabbit anti-CX3CR1 antibody (1: 1000, Abcam, 20 
Cambridge, MA, USA), mouse anti-MOR antibody (1: 500, R&D, Minneapolis, MN, 21 
USA), or rabbit anti-GAPDH (1: 2500, Aspen, Wuhan, China) overnight at 4 °C. After 22 
being thoroughly washed, the membrane was incubated with HRP-conjugated rabbit 23 
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anti-goat IgG (1: 5000, EarthOx, Millbrae, CA, USA), HRP-conjugated goat anti-rabbit 1 
IgG (1: 4000, Aspen, Wuhan, China), or HRP-conjugated goat anti-mouse IgG (1: 1000, 2 
Bioyeartech, Wuhan, China) for 2 h at room temperature. Finally, proteins were 3 
detected by ECL reagents (Beyotime, Wuhan, China) and visualized by exposing to X-4 
ray film. The ImageJ analysis system (NIH, Bethesda, MD) was used for the 5 
quantification of specific bands. The levels of Iba-1, CX3CL1, CX3CR1 and MOR 6 
were exhibited as density relative to the density of GAPDH. 7 
Double immunofluorescent staining 8 
After being treated with morphine or saline for 7 days, rats were perfused with saline, 9 
followed by 4 % ice-cold paraformaldehyde (PFA) in 0.1 M phosphate buffer saline 10 
(PBS) under deep anesthesia with pentobarbital sodium. The L1-L5 spinal cord 11 
segments were removed and post-fixed for 24 h at 4 °C, then dehydrated in 30 % 12 
sucrose solution. After being treated with 0.3 % Triton X-100 and blocked with 10 % 13 
donkey serum for 40 min at room temperature, 25 µm-thick sections were incubated 14 
overnight at 4 °C with mixtures of the following primary antibodies: goat anti-CX3CL1 15 
antibody (1: 25, R&D, Minneapolis, MN, USA) or rabbit anti-CX3CR1 antibody (1: 16 
200, Abcam, Cambridge, MA, USA) and mouse anti-NeuN (1: 200, Millipore, 17 
Bellerica, MA, USA), mouse anti-GFAP (1: 200, CST, Beverly, MA, USA), goat anti-18 
Iba1 (1: 100, Abcam, Cambridge, MA, USA) or rabbit anti-Iba1 (1: 200, Wako, Osaka, 19 
Japan). Then sections were incubated with mixtures of the following secondary 20 
antibodies: Cy3-conjugated donkey anti-goat IgG (1: 300, Proteintech, Wuhan, China) 21 
and FITC-conjugated donkey anti-mouse IgG (1: 100, Proteintech, Wuhan, China) or 22 
FITC-conjugated donkey anti-rabbit IgG (1: 100, Proteintech, Wuhan, China), or 23 
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IFKine Red labeled donkey anti-rabbit IgG (1: 500, Abbkine, Redlands, CA, USA) and 1 
FITC-conjugated donkey anti-mouse IgG (1: 100, Proteintech, Wuhan, China) or FITC-2 
conjugated donkey anti-goat IgG (1: 100, Proteintech, Wuhan, China) for 2 h at room 3 
temperature and stained with 4, 6-diamidino-2-phenylindole (DAPI, Boster, Wuhan, 4 
China) for 10 min. The stained sections were examined by using Fluorescence 5 
Microscope (DM2500, Leica, German) to capture the fluorescent images. Five spinal 6 
sections were selected randomly for each rat and the immunoreactivities of CX3CL1 7 
and CX3CR1 were counted in a blinded fashion [23]. The stained sections were 8 
analyzed by Image Pro Plus 4 software (Media Cybernetics, Maryland, MD, USA). 9 
Microarray mRNA profiling 10 
Gene expression profile of spinal cord tissues was established by using Affymetrix Rat 11 
Genome 230 2.0 Arrays. L1-L5 spinal cord segments of morphine-treated or saline-12 
treated rats were isolated on day 7 and RNAlater RNA Stabilization Reagent (Qiagen, 13 
Germany) was used for stabilization of RNA in tissue samples. Total RNA isolation 14 
was performed with TRIzol reagent (Invitrogen, USA) and NucleoSpin® RNA Clean-15 
up (MACHEREY-NAGEL, Germany). The cRNA was generated and labeled by one-16 
cycle target labeling method. Affymetrix Rat Genome 230 2.0 microarray (CapitalBio 17 
Corporation, Beijing, China) which contains 31,000 probe sets including 65 probe sets 18 
of chemokine family was used to screen the differential expressions of chemokines. 19 
The acceptance criteria for RNA quality were 260/280 ratio ≥ 1.80 and RNA integrity 20 
number ≥ 8.0. The cRNA generated from each sample was hybridized to a single array 21 
according to standard Affymetrix protocols. Initial image analysis of microarray chips 22 
was performed using the Genechip® Command Console® Software. Data were 23 
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exported to Significance Analysis of Microarrays software for screening differentially 1 
expressed genes. The screening criterion was set as fold change ≥ 2 or fold change ≤ 2 
0.5 with false discovery rate (FDR) q-value ≤ 0.05. 3 
Statistical analysis 4 
Animal sample size for behavioral experiment was decided by power analysis using 5 
SSize2021 software (National University of Singapore, Singapore) (version 2). With 6 
anticipated population proportion P1 = 0.95, P2 = 0.05, significance level 0.05 and 7 
power of test 0.09, the sample size was estimated to be four per group. All data were 8 
presented as mean ± SEM. Behavioral test was analyzed by two-way repeated measure 9 
ANOVA (treatment group × time) to detect overall differences among treatment groups 10 
followed by Bonferroni’s test to detect the changes to %MPE after drug injection over 11 
time. The results of qRT-PCR and western blots were analyzed by one-way ANOVA. 12 
Individual comparisons were conducted with unpaired t-test. Statistical analyses were 13 
performed with GraphPad Prism 5 (GraphPad Software Inc.) with statistical 14 
significance set at P < 0.05. 15 
Results 16 
Chronic morphine treatment induced drug tolerance and activated microglia 17 
Rats were intrathecally administered with morphine (10 μg/5 μL) or saline (5 μL) twice 18 
daily for consecutive 7 days. Behavioral tests were conducted before drug 19 
administration and at 30 min after the last drug administration on day 1, 3, 5, and 7. As 20 
shown in Fig. 1A, rats received morphine exhibited significantly higher %MPE 21 
compared with saline-treated rats on day 1 (P < 0.001) and day 3 (P < 0.01). On day 5, 22 
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there was no significant difference of %MPE levels between morphine-treated and 1 
saline-treated rats (P > 0.05), suggesting that chronic morphine tolerance had been 2 
successfully established. Iba-1 is the marker of activated microglia. On day 7, the 3 
increased expression of Iba-1 was detected in spinal cord (Fig. 1B), indicating the 4 
activation of microglia induced by chronic morphine exposure. Previous study has 5 
demonstrated that chronic morphine treatment significantly decreases the expression of 6 
MOR in hypothalamus but not in locus ceruleus and nucleus accumbens [24], 7 
suggesting that the cellular adaptation for morphine is tissue-specific. In this study, we 8 
did not detect any changes in MOR expression in spinal cord of morphine-treated rats 9 
compared to that in saline-treated rats on day 7 (Fig. 1C and 1D). 10 
Chronic morphine treatment did not affect the expressions of CX3CL1 and CX3CR1 11 
Previous studies have demonstrated that CX3CL1 and its receptor could play the 12 
important roles in antinociceptive effects of opioid agonists in periaqueductal grey 13 
[12,25]. To determinate whether CX3CL1 and CX3CR1 participate in the development 14 
of morphine tolerance, the expressions of CX3CL1 and CX3CR1 in spinal cord of rats 15 
were examined on day 7 of morphine administration. As shown in Fig. 2, neither the 16 
levels of CX3CL1 mRNA (F2, 15 = 0.901, P = 0.427) and CX3CR1 mRNA (F2, 15= 1.314, 17 
P = 0.298), nor expressions of CX3CL1 protein (F2, 12 = 0.999, P = 0.397) and CX3CR1 18 
protein (F2, 21= 0.833, P = 0.449) was affected by intrathecal administration of morphine 19 
when compared to saline-treated rats. 20 
Exogenous CX3CL1 or CX3CR1 inhibitor had no effect on behavioral responses during 21 
the development of morphine tolerance 22 
There was no significant difference in baseline levels of tail-flick latency measured 23 
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prior to drug administration among all groups, indicating that intrathecal catheterization 1 
did not affect behavioral responses of rats (Fig. 3A). To further investigate the roles of 2 
CX3CL1 and CX3CR1 in the development of morphine tolerance, recombinant rat 3 
CX3CL1 (100 ng or 500 ng), anti-CX3CR1 neutralizing antibody (5 μg or 10 μg) or 4 
control IgG (100 ng or 5 μg) was intrathecally injected 30 min before morphine 5 
administration, respectively. As shown in Fig. 3B, neither 100 ng nor 500 ng rrCX3CL1 6 
exhibited statistically significant effect on %MPE in rats treated with morphine 7 
compared with that in IgG-morphine treated rats (F2, 45 = 1.498, P = 0.255 for 100 ng 8 
rrCX3CL1; F2, 45 = 0.903, P = 0.426 for 500 ng rrCX3CL1). Moreover, interaction 9 
between rrCX3CL1 treatment and time was not considered significantly (F9, 60 = 0.527, 10 
P = 0.849). As shown in Fig. 3C, there was no significant effect of 5 μg or 10 μg anti-11 
CX3CR1 neutralizing antibody on %MPE in rats treated with morphine when 12 
compared with that in IgG-morphine treated rats (F2, 45 = 0.905, P = 0.426 for 5 μg; F2, 13 
45 = 1.107, P = 0.356 for 10 μg). There was no significant interaction between anti-14 
CX3CR1 neutralizing antibody treatment and time (F9, 60 = 1.770, P = 0.093). These 15 
results suggest that both exogenous CX3CL1 stimulation and CX3CR1 inhibition could 16 
not markedly affect the development of morphine tolerance that assessed by tail flick 17 
test. 18 
Exogenous CX3CL1 or CX3CR1 inhibitor had no influence on the activation of 19 
microglia induced by morphine 20 
In order to further clarify the roles of CX3CL1 and CX3CR1, exogenous CX3CL1 (100 21 
ng or 500 ng) or CX3CR1 inhibitor (5 μg or 10 μg) was intrathecally administered 22 
respectively and their effects on the activation of spinal microglia in morphine tolerant 23 
rats were assessed. As shown in Fig. 4, the expressions of Iba-1 were significantly 24 
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increased in all morphine-treated rats. Neither rrCX3CL1 nor anti-CX3CR1 1 
neutralizing antibody had statistically significant effect on morphine-induced 2 
expressions of Iba-1 (F5, 12 = 0.138, P = 0.980). 3 
Cellular localizations of spinal CX3CL1 and CX3CR1 in morphine tolerant rats 4 
The communication between neurons and glia mediated by CX3CL1 and CX3CR1 5 
contributes to the mechanisms of inflammatory and neuropathic pain [3,26,27]. The 6 
changes of cellular distribution of CX3CL1 and CX3CR1 in spinal cord have also been 7 
reported to be associated with pain conditions [18]. In this study, we examined the 8 
cellular localizations of CX3CL1 and CX3CR1 in rat spinal dorsal horn. The results 9 
showed that CX3CL1 expression was extensively distributed to all layers of spinal 10 
dorsal horn, and CX3CR1 was mainly expressed in lamina I to lamina III of spinal cord 11 
(Fig. 5A). There was no significant difference in the expression of CX3CL1 or 12 
CX3CR1 between morphine-treated rats and saline-treated rats (Fig. 5B). In saline-13 
treated rats, the immunoreactivity of CX3CL1 was co-localized with neuronal marker 14 
NeuN, while CX3CR1 was co-localized with microglia marker Iba-1 (Fig. 5C). 15 
However, both CX3CL1 and CX3CR1 were found to be co-localized with NeuN, GFAP 16 
and Iba-1 in morphine-treated rats (Fig. 5D and 5E). These indicate the shift of 17 
CX3CL1/CX3CR1 expressions occurred during the development of morphine 18 
tolerance. 19 
The mRNA expression profiling screened spinal chemokines related to morphine 20 
tolerance 21 
To screen the possible chemokines which might be involved in the development of 22 
morphine tolerance in spinal cord, mRNA of L1-L5 lumbar spinal cord of respective 23 
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animal was analyzed using microarrays which contains 65 probe sets of chemokines. 1 
As shown in Fig. 6, expressions of 15 chemokines were identified to be upregulated in 2 
morphine-treated rats when compared with saline-treated rats. All the upregulated 3 
genes of chemokine were listed in Table. 1. However, the changes of CX3CL1 and 4 
CX3CR1 expressions were not detected by microarray analysis. 5 
Discussion 6 
The results of our study showed that chronic morphine treatment can induce 7 
antinociceptive tolerance, but did not affect the expressions of CX3CL1 and its receptor 8 
CX3CR1 in spinal cord. Neither intrathecal administration of exogenous CX3CL1 nor 9 
CX3CR1 inhibitor affected the development of morphine tolerance. However, 10 
morphine treatment could influence the cellular localization of CX3CL1 and CX3CR1 11 
in spinal dorsal horn in rats. 12 
 13 
Various signaling pathways have been found to be involved in the mechanism of opioid 14 
tolerance. Opioid tolerance could be prevented, attenuated or reversed by inhibiting 15 
proinflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor α (TNF-α) 16 
[28,29]; blocking the activations of extracellular regulated protein kinases (ERK) and 17 
p38 protein [30-32]; increasing glial glutamate transporter-1 (GLT-1) and glutamate-18 
aspartate transporters (GLAST) [33,34]. Recently, toll-like receptor 4 (TLR4) has been 19 
reported to participate in the development of opioid tolerance via increasing tumor 20 
necrosis factor and IL-1β expressions and downregulating the expressions of GLT-1 21 
and GLAST [35, 36]. Opioid tolerance could be considered as a drug-specific side 22 
effect. The mechanisms of drug tolerance induced by different opioids may be distinct. 23 
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The internalization of MOR, which is the typical feature of opioid tolerance, highly 1 
depends on the type of agonist [37]. Endogenous opioids as well as synthetic peptide 2 
DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin) promote the rapid endocytosis of 3 
MOR, but the highly addictive opioid, such as morphine, fails to induce detectable 4 
endocytosis [38,39]. Changes in MOR expression in response to chronic opioid 5 
treatment have long been speculated to directly contribute to the development of opioid 6 
tolerance. Following chronic treatment with various agonists, the expression of opioid 7 
receptor in brain tissue is either increased, decreased or unchanged, indicating that the 8 
regulation of opioid receptor expression depends on the type of opioid [40], agonist 9 
[41,42], and the region of brain [26,43]. In addition, opioid tolerance is not only due to 10 
the rapid decrease of receptor activity but also the compensatory mechanism 11 
counteracting the function of opioid receptor [44-46]. Therefore, it is reasonable to 12 
comprehend the expression of MOR in spinal cord was unchanged in our study during 13 
the development of morphine tolerance. 14 
 15 
Previous studies have shown that CX3CL1/CX3CR1 signaling axis participate in 16 
numerous physiological and pathological processes, including neuropathic pain [26], 17 
maturation of synaptic connection [47,48], neuronal survival [49], insulin secretion [50] 18 
and atherosclerosis [51]. However, our results revealed the unchanged expressions of 19 
CX3CL1 and CX3CR1 in spinal cord of morphine tolerant rats. Recently study in 20 
opioid tolerant patients also showed that the concentration of CX3CL1 in cerebrospinal 21 
fluid is not significantly different from that in naïve-control patients [6]. Although 22 
previous study reported that intrathecal administration of 30 ng exogenous CX3CL1 23 
could induce the behavioral effects such as mechanical allodynia and thermal 24 
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hyperalgesia [4], the development of morphine tolerance was not affected by much 1 
higher doses of exogenous CX3CL1 in our study. Previous study showed that 2 
intrathecal administration of 3 μg anti-CX3CR1 neutralizing antibody could effectively 3 
inhibit monoarthritis-induced mechanical allodynia and thermal hyperalgesia [3], 4 
which illustrates that the doses of anti-CX3CR1 neutralizing antibody used in our study 5 
(5 μg and 10 μg) should be sufficient to block the function of CX3CR1 in spinal cord. 6 
However, in our study, intrathecal injection of CX3CR1 inhibitor did not affect either 7 
the antinociceptive effect of morphine or the development of morphine tolerance. In 8 
contrast, Johnston and colleagues reported that intrathecal injection of anti-CX3CR1 9 
neutralizing antibody could attenuate the development of morphine tolerance [20]. This 10 
discrepancy might be due to the different experimental protocols including the 11 
evaluation of pain threshold. In Johnston’s study, tail flick latencies were recorded 12 
every 20 min for 2 hours after morphine infusions to calculate the average response 13 
over this time on day 1 and day 5. Their behavioral assessment protocol is quite 14 
different from ours which has been most commonly used in the previous studies 15 
[21,22,37]. The analgesic effect of morphine occurs at 5 minutes after intrathecal 16 
injection, lasts for about 60 minutes, and dissipates by 100 minutes [29]. Choosing the 17 
average value of tail flick latencies over 2 hours as the pain threshold of morphine-18 
treated rats may fail to represent the maximum analgesic potency of morphine. Taken 19 
together, CX3CL1 and its receptor CX3CR1 in spinal cord may not participate in the 20 
mechanism of morphine tolerance directly. Although sufficient dosages of exogenous 21 
CX3CL1 and anti-CX3CR1 neutralizing antibody were used in our study, we could not 22 
definitively exclude the possibility that CX3CL1/CX3CR1 signaling play a positive 23 
role in the mechanism of morphine tolerance yet. CX3CL1 or CX3CR1 knockout 24 
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animals might be the ideal option to verify the role of CX3CL1/CX3CR1 in morphine 1 
tolerance. 2 
 3 
Under physiological conditions, expression of CX3CL1 in spinal cord appears to be 4 
restricted to neurons, whereas CX3CR1 in microglia [18]. However, CX3CL1 could be 5 
detected not only in neurons but also in astrocytes after spinal nerve ligation [10], 6 
suggesting that the distribution of CX3CL1 and CX3CR1 may depend on the diverse 7 
pathological processes. Both CX3CR1 and opioid receptors are members of G protein 8 
coupled receptor family. The formation of heterodimer among G protein coupled 9 
receptors are common. Previous study has found the MOR-CX3CR1 co-localization on 10 
neurons in several brain regions, including nucleus accumbens, ventral tegmental area 11 
and periaqueductal gray and MOR-CX3CR1 heterologous desensitization has been 12 
proved in periaqueductal gray [25]. We found that the cellular localizations of spinal 13 
CX3CL1 and CX3CR1 changed from neuron and microglia, respectively, to all the 14 
neural cells after chronic morphine administration. These findings support the 15 
possibility that morphine treatment may stimulate the cleavage of CX3CL1 in neurons 16 
[26] and promote the combination of CX3CL1 with its receptor on glia. It has been 17 
reported that simultaneous activations of delta opioid receptor (DOR) and CXCR4 on 18 
human peripheral blood mononuclear cells could promote the formation of non-19 
functional DOR-CXCR4 heterodimers which are unable to respond to the agonists [52]. 20 
Therefore, we speculate that the newly expressed CX3CR1 on neuron may bind to 21 
MOR to form into the heterodimer, which at least partly contribute to morphine 22 
analgesia or tolerance. Further studies are still needed to explore the potential 23 
interaction between CX3CR1 and opioid receptor in the mechanism of morphine 24 
18 
 
tolerance. 1 
 2 
Chemokines and opioids are effective regulators of immune, inflammatory and 3 
neuronal responses in pain mechanism in central nervous system. Several chemokines 4 
could increase the neuronal excitability and subsequently decrease opioid analgesic 5 
efficacy, which may act as the key neuromodulators of pain pathways [53]. 6 
Administration of CCL5 or CXCL12 (binding to CCR1 or CXCR4, respectively) into 7 
periaqueductal gray could attenuate acute opioid analgesia via heterologous 8 
desensitization of opioid receptors [54,55]. Spinal glial CXCL12 has also been reported 9 
to be associated with pain hypersensitivity process induced by bone cancer [56]. Other 10 
evidences indicate that CXCL10 could serve as a negative regulator of morphine 11 
analgesia [7]. Intrathecal administration of CCL2 neutralizing antibody could attenuate 12 
the development of morphine tolerance [21]. Our microarrays analysis revealed the 13 
expressions of 15 chemokines, which mainly belong to CXC and CC subfamilies, were 14 
significantly increased due to chronic morphine exposure. These results further 15 
excluded the direct involvement of CX3CL1 and CX3CR1 in the mechanism of 16 
morphine tolerance and also indicated the potential contribution of chemokines to the 17 
development of morphine tolerance. 18 
 19 
In conclusion, our study reveals that chronic morphine exposure did not alter the 20 
expressions of CX3CL1 and CX3CR1 in spinal cord and inhibiting CX3CL1 or 21 
CX3CR1 could not affect the morphine analgesia and the development of drug 22 
tolerance. But morphine could change the cellular localizations of spinal CX3CL1 and 23 
CX3CR1 which indicates the complex interaction between neuron and glia during 24 
19 
 
morphine tolerance. We also found that 15 chemokines were upregulated significantly 1 
during the development of morphine tolerant. These might provide the potential 2 
research targets for the further studies in morphine tolerance in the future. 3 
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 18 
Figure 1. Expressions of MOR and Iba-1 in lumbar spinal cord of rats. 19 
A. Thermal pain threshold of rats was assessed using the percentage of maximal 20 
30 
 
possible antinociceptive effect (%MPE) according to the tail-flick latency of rats. 1 
The %MPE in rats received morphine (10 μg, twice daily, intrathecally) on day 5 and 7 2 
were dramatically decreased compared with the baseline on day 1. Values represent 3 
mean ± SEM; two-way ANOVA, ** P < 0.01, *** P < 0.001, vs. naïve and sham, n = 4 
6 in each group. B. The expression of Iba-1 protein was significantly increased in 5 
morphine-treated rats measured by Western blots. Values represent mean ± SEM; 6 
ANOVA, * P < 0.05 vs. naïve and sham, n = 6 in each group. C and D. The expressions 7 
of MOR mRNA (C) and protein (D) were not affected by morphine treatment measured 8 
by real-time PCR and Western blots, respectively. Values represent mean ± SEM; 9 
ANOVA, * P < 0.05 vs. naïve and sham, n = 6 in each group. 10 
 11 
Figure 2. Expressions of CX3CL1 and CX3CR1 in lumbar spinal cord of rats. 12 
A. The expressions of CX3CL1 and CX3CR1 mRNA were not affected by morphine 13 
treatment measured by real-time PCR. Values represent mean ± SEM; ANOVA, *P < 14 
0.05 vs. naïve and sham, n = 6 in each group. B and C. The expressions of CX3CR1 15 
(B) and CX3CL1 (C) protein were not affected by morphine treatment measured by 16 
Western blots. Values represent mean ± SEM; ANOVA, * P < 0.05 vs. naïve and sham, 17 
n = 8 in each group for CX3CR1, n = 5 in each group for CX3CL1. 18 
 19 
Figure 3. Effects of recombinant rat CX3CL1 and anti-CX3CR1 neutralizing 20 
antibody on the development of morphine tolerance. 21 
A. Tail flick latency of rats in each group did not change after intrathecal catheterization. 22 
B and C. Recombinant rat CX3CL1 (100 ng or 500 ng) (B), anti-CX3CR1 neutralizing 23 
antibody (5 μg or 10 μg) (C) or normal IgG (100 ng for rrCX3CL1 group, 5 μg for anti-24 
31 
 
CX3CR1 neutralizing antibody group as control dose.) was intrathecally administered 1 
30 minutes before morphine treatment for 7 days. None of them significantly affected 2 
morphine antinociception or alleviated the development of morphine tolerance. Values 3 
represent mean ± SEM; two-way ANOVA, *** P < 0.001, * P < 0.05 vs. naïve and 4 
sham, n = 6 in each group. 5 
 6 
Figure 4. Effects of exogenous CX3CL1 and CX3CR1 inhibitor on the microglia 7 
activation with repeated morphine administration for 7 consecutive days. 8 
Exogenous CX3CL1 (100 ng or 500 ng), CX3CR1 inhibitor (5 μg or 10 μg) and IgG (5 9 
μg) were administered 30 minutes before morphine treatment for 7day, respectively. 10 
Microglia activity was increased significantly in morphine involved groups. However, 11 
both exogenous CX3CL1 and CX3CR1 inhibitor showed no influence in quantification 12 
of Iba-1 levels from Western blots compared to morphine treated rats. Values represent 13 
mean ± SEM; one-way ANOVA, * P < 0.05 vs. sham, n = 3 in each group. 14 
 15 
Figure 5. Changes in the cellular localizations of CX3CL1 and CX3CR1 during 16 
the development of morphine tolerance. 17 
A and B. Expressions of CX3CL1 and CX3CR1 in the spinal cord. There were no 18 
changes in the number of CX3CL1 (a, b) and CX3CR1 (c, d) immunoreactive cells in 19 
spinal dorsal horn of morphine-tolerant rats compared with those in sham rats (n = 3, 20 
scale bar 200 μm). C. Double immunostaining of CX3CL1 (a, b, c) or CX3CR1 (d, e, 21 
f) and cell-specific markers in the spinal cord in saline-treated rats. CX3CL1 was co-22 
localized with NeuN and CX3CR1 was co-localized with Iba-1. a: CX3CL1 and NeuN; 23 
b: CX3CL1 and GFAP; c: CX3CL1 and Iba-1; d: CX3CR1 and NeuN; e: CX3CR1 and 24 
32 
 
GFAP; f: CX3CR1 and Iba-1. Scale bar: 200 μm. D. Double immunostaining of 1 
CX3CL1 and cell-specific markers in morphine-treated rats. CX3CL1 was co-localized 2 
with NeuN, GFAP and Iba-1 (indicated by arrows). a, e and i: CX3CL1; b: NeuN; f: 3 
GFAP; j: Iba-1; c and d: CX3CL1 merged with NeuN; g and h: CX3CL1 merged with 4 
GFAP; k and l: CX3CL1 merged with Iba-1. Scale bars: 200 μm (a, b, c, e, f, g, i, j and 5 
k); scale bar: 100 μm (d, h and l). E. Double immunostaining of CX3CR1 and cell-6 
specific markers in morphine-treated rats. CX3CR1 was co-localized with NeuN, GFAP 7 
and Iba-1 (indicated by arrows). a, e and i: CX3CR1; b: NeuN; f: GFAP; j: Iba-1; c and 8 
d: CX3CR1 merged with NeuN; g and h: CX3CR1 merged with GFAP; k and l: 9 
CX3CR1 merged with Iba-1. Scale bar: 200 μm (a, b, c, e, f, g, i, j and k); scale bar: 10 
100 μm (d, h and l). 11 
 12 
Figure 6. Heatmap of expression ratios of chemokines family mRNAs. 13 
The probe sets that expressions were changed in morphine tolerance rats were identified 14 
by microarray analysis. Probe sets with similar expression profiles were clustered 15 
together using a Pearson’s correlation-based method with Cluster 3.0 and TreeView 16 
software. The expression level of each chemokine probe set was displayed as a log2 17 
ratio of their expression values divided by their expression values in sham rats. 18 
